Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform
More News related to OPTR
- Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
- Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
- Morning Movers 11/12: NLST, HPJ, COMS, AMD, CAAS Higher; TRMS, NWPX, ATRN, BRCD, CDTI, GMCR Lower
- Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection
- Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
Oppenheimer downgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Outperform to Perform.
To see more analyst ratings on OPTR Click Here.
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide.
Related Categories
DowngradesStocks Mentioned
-0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
